Cargando…
Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies
Pancreatic tumors are highly desmoplastic and immunosuppressive. Delivery and distribution of drugs within pancreatic tumors are compromised due to intrinsic physical and biochemical stresses that lead to increased interstitial fluid pressure, vascular compression, and hypoxia. Immunotherapy-based a...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771545/ https://www.ncbi.nlm.nih.gov/pubmed/35154473 http://dx.doi.org/10.7150/thno.64805 |
_version_ | 1784635627617124352 |
---|---|
author | Liu, Luman Kshirsagar, Prakash G. Gautam, Shailendra K. Gulati, Mansi Wafa, Emad I. Christiansen, John C. White, Brianna M. Mallapragada, Surya K. Wannemuehler, Michael J. Kumar, Sushil Solheim, Joyce C. Batra, Surinder K. Salem, Aliasger K. Narasimhan, Balaji Jain, Maneesh |
author_facet | Liu, Luman Kshirsagar, Prakash G. Gautam, Shailendra K. Gulati, Mansi Wafa, Emad I. Christiansen, John C. White, Brianna M. Mallapragada, Surya K. Wannemuehler, Michael J. Kumar, Sushil Solheim, Joyce C. Batra, Surinder K. Salem, Aliasger K. Narasimhan, Balaji Jain, Maneesh |
author_sort | Liu, Luman |
collection | PubMed |
description | Pancreatic tumors are highly desmoplastic and immunosuppressive. Delivery and distribution of drugs within pancreatic tumors are compromised due to intrinsic physical and biochemical stresses that lead to increased interstitial fluid pressure, vascular compression, and hypoxia. Immunotherapy-based approaches, including therapeutic vaccines, immune checkpoint inhibition, CAR-T cell therapy, and adoptive T cell therapies, are challenged by an immunosuppressive tumor microenvironment. Together, extensive fibrosis and immunosuppression present major challenges to developing treatments for pancreatic cancer. In this context, nanoparticles have been extensively studied as delivery platforms and adjuvants for cancer and other disease therapies. Recent advances in nanotechnology have led to the development of multiple nanocarrier-based formulations that not only improve drug delivery but also enhance immunotherapy-based approaches for pancreatic cancer. This review discusses and critically analyzes the novel nanoscale strategies that have been used for drug delivery and immunomodulation to improve treatment efficacy, including newly emerging immunotherapy-based approaches. This review also presents important perspectives on future research directions that will guide the rational design of novel and robust nanoscale platforms to treat pancreatic tumors, particularly with respect to targeted therapies and immunotherapies. These insights will inform the next generation of clinical treatments to help patients manage this debilitating disease and enhance survival rates. |
format | Online Article Text |
id | pubmed-8771545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-87715452022-02-10 Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies Liu, Luman Kshirsagar, Prakash G. Gautam, Shailendra K. Gulati, Mansi Wafa, Emad I. Christiansen, John C. White, Brianna M. Mallapragada, Surya K. Wannemuehler, Michael J. Kumar, Sushil Solheim, Joyce C. Batra, Surinder K. Salem, Aliasger K. Narasimhan, Balaji Jain, Maneesh Theranostics Review Pancreatic tumors are highly desmoplastic and immunosuppressive. Delivery and distribution of drugs within pancreatic tumors are compromised due to intrinsic physical and biochemical stresses that lead to increased interstitial fluid pressure, vascular compression, and hypoxia. Immunotherapy-based approaches, including therapeutic vaccines, immune checkpoint inhibition, CAR-T cell therapy, and adoptive T cell therapies, are challenged by an immunosuppressive tumor microenvironment. Together, extensive fibrosis and immunosuppression present major challenges to developing treatments for pancreatic cancer. In this context, nanoparticles have been extensively studied as delivery platforms and adjuvants for cancer and other disease therapies. Recent advances in nanotechnology have led to the development of multiple nanocarrier-based formulations that not only improve drug delivery but also enhance immunotherapy-based approaches for pancreatic cancer. This review discusses and critically analyzes the novel nanoscale strategies that have been used for drug delivery and immunomodulation to improve treatment efficacy, including newly emerging immunotherapy-based approaches. This review also presents important perspectives on future research directions that will guide the rational design of novel and robust nanoscale platforms to treat pancreatic tumors, particularly with respect to targeted therapies and immunotherapies. These insights will inform the next generation of clinical treatments to help patients manage this debilitating disease and enhance survival rates. Ivyspring International Publisher 2022-01-01 /pmc/articles/PMC8771545/ /pubmed/35154473 http://dx.doi.org/10.7150/thno.64805 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Liu, Luman Kshirsagar, Prakash G. Gautam, Shailendra K. Gulati, Mansi Wafa, Emad I. Christiansen, John C. White, Brianna M. Mallapragada, Surya K. Wannemuehler, Michael J. Kumar, Sushil Solheim, Joyce C. Batra, Surinder K. Salem, Aliasger K. Narasimhan, Balaji Jain, Maneesh Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies |
title | Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies |
title_full | Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies |
title_fullStr | Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies |
title_full_unstemmed | Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies |
title_short | Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies |
title_sort | nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771545/ https://www.ncbi.nlm.nih.gov/pubmed/35154473 http://dx.doi.org/10.7150/thno.64805 |
work_keys_str_mv | AT liuluman nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT kshirsagarprakashg nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT gautamshailendrak nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT gulatimansi nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT wafaemadi nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT christiansenjohnc nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT whitebriannam nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT mallapragadasuryak nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT wannemuehlermichaelj nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT kumarsushil nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT solheimjoycec nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT batrasurinderk nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT salemaliasgerk nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT narasimhanbalaji nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies AT jainmaneesh nanocarriersforpancreaticcancerimagingtreatmentsandimmunotherapies |